Compliance for Life(TM) Medication Dosing Reminders Go Global

* Reuters is not responsible for the content in this press release.

Tue Jul 22, 2008 10:26am EDT

Personalized Reminders Delivered to Clinical Trials Participants
                 and International Travelers Worldwide
WESTFIELD, N.J.--(Business Wire)--
Compliance for Life(TM) is going global. iReminder, LLC, announces
that Compliance for Life now delivers dosing reminders anywhere in the
world by phone and SMS text message, as well as email. Compliance for
Life is a scalable, patient-centric system that reminds and motivates
people to fill, refill and take their prescriptions, go to medical
appointments and complete other medically-necessary tasks.

   Worldwide clinical trial participants and international travelers
have full access to Compliance for Life, including its personalization
features, scheduling flexibility, two-way communications and personal
healthcare networks. As in the U.S., international users reply whether
or not they have taken their medication, and their progress can be
monitored by family members, health coaches, medical providers or
principal investigators.

   "We are filling an unmet need for better medication therapy
management by delivering dosing reminders to people around the world
via all three contact methods - phone, SMS text messages and email,"
said Amy J. Yoffie, CEO of iReminder. "Users don't need any special
equipment to receive or reply to reminders, which are delivered in the
recipient's language. Letting users pick the language of their
reminders is yet another unique personalization feature of Compliance
for Life to motivate ongoing compliance anywhere in the world."

   All core personalization features are available in any language,
including reminders delivered in the voice of the person who sets them
up, messages that can be as specific as needed for the person
receiving them and a customizable delivery sequence that "finds" users
even when their daily routines change. Messages can be recorded and
delivered in any language.

   Yoffie added: "Here in the U.S. health plans are adopting
pay-for-performance (P4P) incentives, encouraging providers to improve
Rx compliance with proactive medication therapy management (MTM).
Value-based health plans are focusing on up-front spending that avoids
long-term, higher costs. Compliance for Life helps patients better
understand and comply with their medication regimens to prevent
chronic conditions from escalating, improve their health and reduce
costs across all healthcare sectors.

   iReminder markets Compliance for Life to managed care
organizations, pharmacy benefit managers, pharmaceutical manufacturers
and distributors, pharmacy chains and companies with self-insured
health benefits that in turn distribute it to their constituents. It
also is marketed to companies conducting clinical trials and
government agencies.

   iReminder offers an SaaS (software as a service) model so that
licensees can adopt Compliance for Life's patent-pending technology
without burdening their IT departments. By using a proprietary
VXML-based IVR system, Compliance for Life can send phone and text
reminders through customers' trunk lines to take advantage of their
low telecommunications fees. Licensees may private label the system.

   About iReminder, LLC

   iReminder, LLC, a healthcare technology company, has developed
Compliance for Life(TM) (CFL), a solution to the epidemic of
medication non-adherence. This patient-centric system addresses key
reasons for non-compliance: forgetfulness, changes in patients' daily
routines and lack of ongoing support. Licensed to companies with
rising healthcare costs and those losing revenue due to
non-compliance, it achieves scalability through technology. CFL serves
a huge, underserved market of busy, active people who take daily
medications. For more information, visit www.iReminder.com or call
877-326-3293.

iReminder, LLC
Amy J. Yoffie, CEO
Phone: 877-326-3293
Cell: 908-705-1954
http://www.iReminder.com
amy@iReminder.com

Copyright Business Wire 2008
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.